SEARCH:   Advanced

Blood, 15 September 2006, Vol. 108, No. 6, pp. 2037-2040. Prepublished online as a Blood First Edition Paper on May 18, 2006; DOI 10.1182/blood-2006-03-009860. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-03-009860v1 108/6/2037    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kiladjian, J.-J. Articles by Fenaux, P. Search for Related Content PubMed PubMed Citation Articles by Kiladjian, J.-J. Articles by Fenaux, P. Related Collections Neoplasia Brief Reports Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Brief report High molecular response rate of polycythemia vera patients treated with pegylated interferon –2a Jean-Jacques Kiladjian, Bruno Cassinat, Pascal Turlure, Nathalie Cambier, Murielle Roussel, Sylvia Bellucci, Marie-Laurence Menot, Gerald Massonnet, Jean-Luc Dutel, Kamel Ghomari, Philippe Rousselot, Marie-Jose Grange, Yasmina Chait, William Vainchenker, Nathalie Parquet, Lina Abdelkader-Aljassem, Jean-François Bernard, Jean-Didier Rain, Sylvie Chevret, Christine Chomienne, and Pierre Fenaux From the AP-HP, Hôpital Avicenne, Service d'Hématologie Clinique, Bobigny, France; Paris 13 University, Paris, France; Assistance Publique–Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Unité de Biologie Cellulaire, Paris, France; CHU Dupuytren, Service d'Hématologie, Limoges, France; Centre Hospitalier Universitaire (CHU) de Lille, Hopital Huriez, Service des Maladies du Sang, Lille, France; AP-HP, Hôpital Lariboisiere, Service d'Hématologie, Paris, France; CH de Beauvais, Service d'Hématologie, Beauvais, France; CH de Versailles, Service d'Hématologie, Versailles, France; AP-HP, Hôpital Bichat, Paris, France; CH de Montfermeil, Service d'Hématologie, Montfermeil, France; Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 790 (U790), Institut Gustave Roussy, Villejuif, France; AP-HP, Hôpital Saint-Louis, Therapie Cellulaire, Paris, France; CH de Chartres, Service d'Hématologie, Chartres, France; and AP-HP, Hôpital Saint-Louis, Département de Biostatistique et Informatique Medicale (DBIM), Paris, France. V617F JAK2 mutation is a reliable molecular marker of polycythemia vera (PV), potentially useful to monitor the effect of treatments in this disease. In a phase 2 study of pegylated (peg) IFN-–2a in PV, we performed prospective sequential quantitative evaluation of the percentage of mutated JAK2 allele (%V617F) by real-time polymerase chain reaction (PCR). The %V617F decreased in 24 (89%) of 27 treated patients, from a mean of 49% to a mean of 27% (mean decrease of 44%; P < .001), and no evidence for a plateau was observed. In one patient, mutant JAK2 was no longer detectable after 12 months. In 3 patients homozygous for the mutation, reappearance of 50% of wild-type allele was observed during treatment. The results seem to confirm the hypothesis that IFN- preferentially targets the malignant clone in PV and show that %V617F assessment using a quantitative method may provide the first tool to monitor minimal residual disease in PV. This trial was registered at www.clinicaltrials.gov as #NCT00241241 [ClinicalTrials.gov] . CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Searching for polycythemia vera's Holy Grail Ronald Hoffman Blood 2006 108: 1792-1793. [Full Text] [PDF] This article has been cited by other articles: J.-J. Kiladjian, F. Cervantes, F. W. G. Leebeek, C. Marzac, B. Cassinat, S. Chevret, D. Cazals-Hatem, A. Plessier, J.-C. Garcia-Pagan, S. D. Murad, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases Blood, May 15, 2008; 111(10): 4922 - 4929. [Abstract] [Full Text] [PDF] E. Antonioli, P. Guglielmelli, G. Poli, C. Bogani, A. Pancrazzi, G. Longo, V. Ponziani, L. Tozzi, L. Pieri, V. Santini, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia Haematologica, January 1, 2008; 93(1): 41 - 48. [Abstract] [Full Text] [PDF] G. Helbig, B. Stella-Holowiecka, M. Majewski, M. Lewandowska, and J. Holowiecki Interferon {alpha} induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation Haematologica, November 1, 2007; 92(11): e118 - e119. [Abstract] [Full Text] [PDF] G. Finazzi and T. Barbui How I treat patients with polycythemia vera Blood, June 15, 2007; 109(12): 5104 - 5111. [Abstract] [Full Text] [PDF] R. A. Mesa Navigating the Evolving Paradigms in the Diagnosis and Treatment of Myeloproliferative Disorders Hematology, January 1, 2007; 2007(1): 355 - 362. [Abstract] [Full Text] [PDF] P. J. Campbell and A. R. Green The Myeloproliferative Disorders N. Engl. J. Med., December 7, 2006; 355(23): 2452 - 2466. [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020